CEO, Frédéric Amar, has converted part of his loan notes into 2.5 million shares to support the business and L1 Capital has continued financing the Company.

Amsterdam, The Netherlands – 30 June 2019

Esperite NV (Euronext: ESP, “Esperite” or “the Group”) has published its financial results (unaudited) for the period of six months ended June 30, 2018 showing a decrease in total revenue to EUR 5,3 million, and cost of sales maintained at 58 %.

The negative EBITDA of EUR -4,8 million was balanced by the external financing which is expected to support the on-going development.

CryoSave is continuing to consolidate its distribution network and reduce its cost base.

Even though, the restructuring and consolidation of the different activities have lead to a reduction of the current OPEX, provisions for VAT claims have been made in Bulgaria leading to a stable OPEX figure of EUR 7,9 million.

Despite that, the predictive medicine and R&D activities remain promising.

Genoma Swiss Biotechnology’s unique proprietary technology allowed the Group to launch successfully a new development of its new Diagnostic System for Genetic Clinical Laboratories, AGAATA Dx, which now offers CE-IVD diagnostic tests in oncology especially for breast cancer and colorectal cancer and has machine learning capabilities.

The Cell Factory has launched its second generation of EV drugs for future treatment of stroke and Crohn disease.

Frédéric Amar, CEO of Esperite Group, declares: “Esperite has continued to experience turbulent headwind. Our goal is to focus on our unique and advanced technology in predictive medicine.”

Amsterdam, The Netherlands – 30 June 2019